ANG Lifesciences India Limited (BOM:540694)
India · Delayed Price · Currency is INR 34.09
+0.66 (1.97%)
At close: Sep 4, 2026
ANG Lifesciences India Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | -124.13 | -101.43 | -2.62 | 403.17 | 70.28 |
Depreciation & Amortization | 62.7 | 83.71 | 93.54 | 58.75 | 13.17 |
Loss (Gain) From Sale of Assets | - | - | -8.44 | 1.06 | - |
Provision & Write-off of Bad Debts | 4.52 | 10.95 | 9.76 | 21.37 | - |
Other Operating Activities | -7.86 | -35.51 | 106.4 | 213.35 | 28.97 |
Change in Accounts Receivable | 62.86 | 114.22 | 179.31 | -452.18 | -126.79 |
Change in Inventory | -63.43 | 7.21 | -115.28 | -177 | -92.54 |
Change in Accounts Payable | -5.92 | -44.03 | -22.21 | 253.31 | 142.51 |
Change in Other Net Operating Assets | 68.7 | -130.08 | 23.33 | -74.65 | 55.85 |
Operating Cash Flow | -2.56 | -94.95 | 263.77 | 247.17 | 91.44 |
Operating Cash Flow Growth | - | - | 6.72% | 170.31% | 89.29% |
Investing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Capital Expenditures | -37.51 | -55.69 | -104.45 | -413.45 | -42.44 |
Sale of Property, Plant & Equipment | - | 244.96 | - | - | - |
Investment in Securities | 19.38 | 4.37 | 4.53 | -34.34 | -35 |
Other Investing Activities | 2.26 | 5.28 | 6.67 | 3.68 | 0.49 |
Investing Cash Flow | -15.87 | 198.92 | -93.25 | -444.1 | -76.95 |
Financing Activities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Short-Term Debt Issued | 55.58 | 53.97 | - | 175.14 | - |
Long-Term Debt Issued | 56.3 | - | - | 114.08 | 39.55 |
Total Debt Issued | 111.88 | 53.97 | - | 289.22 | 39.55 |
Short-Term Debt Repaid | - | - | -16.56 | - | - |
Long-Term Debt Repaid | -11.31 | -51.59 | -56.69 | - | -21.76 |
Total Debt Repaid | -11.31 | -51.59 | -73.25 | - | -21.76 |
Net Debt Issued (Repaid) | 100.57 | 2.38 | -73.25 | 289.22 | 17.79 |
Issuance of Common Stock | - | - | 20 | - | - |
Common Dividends Paid | - | - | - | -10.35 | - |
Other Financing Activities | -83.75 | -106.4 | -117.49 | -79.59 | -29.66 |
Financing Cash Flow | 16.82 | -104.03 | -170.74 | 199.28 | -11.86 |
Net Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Cash Flow | -1.61 | -0.06 | -0.22 | 2.35 | 2.62 |
Free Cash Flow
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Free Cash Flow | -40.07 | -150.63 | 159.33 | -166.28 | 49 |
Free Cash Flow Growth | - | - | - | - | 53.66% |
Free Cash Flow Margin | -4.32% | -10.31% | 7.25% | -4.69% | 3.17% |
Free Cash Flow Per Share | -3.07 | -11.54 | 12.26 | -12.83 | 3.78 |
Levered Free Cash Flow | -35.87 | -211.96 | 92.18 | -206.34 | -197.58 |
Unlevered Free Cash Flow | 19.63 | -147.45 | 162.13 | -154.59 | -178.37 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Cash Interest Paid | 83.75 | 106.4 | 117.49 | 79.59 | 29.66 |
Cash Income Tax Paid | 42.27 | 134.1 | 34.59 | 5.27 | 31.8 |
Change in Working Capital | 62.21 | -52.68 | 65.15 | -450.53 | -20.98 |